246 related articles for article (PubMed ID: 27355232)
21. [Patient support for primary immunodeficiency with hypogammaglobulinemia and intravenous immunoglobulin substitution: result of a national survey].
Suarez F; Puget S; Beaudet R; Goulamhoussen N; Hermine O
Presse Med; 2010 Mar; 39(3):e45-51. PubMed ID: 20122813
[TBL] [Abstract][Full Text] [Related]
22. 7th International Immunoglobulin Conference: Immunodeficiencies.
Schmidt RE; Ochs HD
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):3-4. PubMed ID: 25546741
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies.
Berger M; Rojavin M; Kiessling P; Zenker O
Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644
[TBL] [Abstract][Full Text] [Related]
24. Managing cost of care and healthcare utilization in patients using immunoglobulin agents.
Vaughan LJ
Am J Manag Care; 2019 Jun; 25(6 Suppl):S105-S111. PubMed ID: 31318516
[TBL] [Abstract][Full Text] [Related]
25. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases.
Shillitoe B; Hollingsworth R; Foster M; Garcez T; Guzman D; Edgar JD; Buckland M
Clin Med (Lond); 2018 Oct; 18(5):364-370. PubMed ID: 30287427
[TBL] [Abstract][Full Text] [Related]
26. Comprehensive activities to increase recognition of primary immunodeficiency and access to immunoglobulin replacement therapy in Poland.
Pac M; Bernatowska E
Eur J Pediatr; 2016 Aug; 175(8):1099-105. PubMed ID: 27357411
[TBL] [Abstract][Full Text] [Related]
27. Disease burden for patients with primary immunodeficiency diseases identified at reference hospitals in Guanajuato, Mexico.
Guaní-Guerra E; Jiménez-Romero AI; García-Ramírez UN; Velázquez-Ávalos JM; Martínez-Guzmán E; Sandoval-Ramírez E; Camacho-Meza I
PLoS One; 2017; 12(4):e0175867. PubMed ID: 28448570
[TBL] [Abstract][Full Text] [Related]
28. Survey of clinical allergy services provided by clinical immunologists in the UK.
El-Shanawany TM; Arnold H; Carne E; Misbah SA; Egner W; Wallington TB; Herriot R; Williams PE
J Clin Pathol; 2005 Dec; 58(12):1283-90. PubMed ID: 16311348
[TBL] [Abstract][Full Text] [Related]
29. The autoimmune rheumatological presentation of Common Variable Immunodeficiency Disorders with an overview of genetic testing.
Ameratunga R; Woon ST; Leung E; Lea E; Chan L; Mehrtens J; Longhurst HJ; Steele R; Lehnert K; Lindsay K
Semin Arthritis Rheum; 2024 Apr; 65():152387. PubMed ID: 38330740
[TBL] [Abstract][Full Text] [Related]
30. Immunoglobulin replacement treatment by rapid subcutaneous infusion.
Gaspar J; Gerritsen B; Jones A
Arch Dis Child; 1998 Jul; 79(1):48-51. PubMed ID: 9771252
[TBL] [Abstract][Full Text] [Related]
31. 20% subcutaneous immunoglobulin for patients with primary immunodeficiency diseases: A systematic review.
Song J; Zhang L; Li Y; Quan S; Liang Y; Zeng L; Liu Y
Int Immunopharmacol; 2015 Apr; 25(2):457-64. PubMed ID: 25633961
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
Shapiro RS
Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
[TBL] [Abstract][Full Text] [Related]
33. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy.
Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL
Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021
[TBL] [Abstract][Full Text] [Related]
34. Pneumococcal antibody levels in children with PID receiving immunoglobulin.
Tuerlinckx D; Florkin B; Ferster A; De Schutter I; Chantrain C; Haerynck F; Philippet P; Strengers P; Laub R
Pediatrics; 2014 Jan; 133(1):e154-62. PubMed ID: 24366995
[TBL] [Abstract][Full Text] [Related]
35. [IgIV at home:experience of a center--economic aspects].
Hachulla E
Rev Med Interne; 2007 May; 28 Spec No. 1():7-10. PubMed ID: 17768832
[TBL] [Abstract][Full Text] [Related]
36. Long-term follow-up of ninety eight Iranian patients with primary immune deficiency in a single tertiary centre.
Nabavi M; Arshi S; Bemanian MH; Aghamohammadi A; Mansouri D; Hedayat M; Nateghian A; Noorbakhsh S; Ehsanipour F; Faranoush M; Shakeri R; Mesdaghi M; Taghvaei B; Ghalebaghi B; Babaie D; Bahrami A; Fallahpour M; Esmaeilzadeh H; Ali Hamidieh A; Rekabi M; Ahmadian J; Eslami N; Shokri S; Afshar M; Jalali F; Akbarpour N; Molatefi R; Rezaei N
Allergol Immunopathol (Madr); 2016; 44(4):322-30. PubMed ID: 26803694
[TBL] [Abstract][Full Text] [Related]
37. Primary immunodeficiency diseases in Australia and New Zealand.
Kirkpatrick P; Riminton S
J Clin Immunol; 2007 Sep; 27(5):517-24. PubMed ID: 17588141
[TBL] [Abstract][Full Text] [Related]
38. 7th International Immunoglobulin Conference: Poster presentations.
Warnatz K; Ballow M; Stangel M; Bril V
Clin Exp Immunol; 2014 Dec; 178 Suppl 1(Suppl 1):162. PubMed ID: 25546805
[TBL] [Abstract][Full Text] [Related]
39. Implications to payers of switch from hospital-based intravenous immunoglobulin to home-based subcutaneous immunoglobulin therapy in patients with primary and secondary immunodeficiencies in Canada.
Gerth WC; Betschel SD; Zbrozek AS
Allergy Asthma Clin Immunol; 2014; 10(1):23. PubMed ID: 24872821
[TBL] [Abstract][Full Text] [Related]
40. Comparison of Diagnostic Criteria for Common Variable Immunodeficiency Disorders (CVID) in the New Zealand CVID Cohort Study.
Ameratunga R; Longhurst H; Steele R; Woon ST
Clin Rev Allergy Immunol; 2021 Oct; 61(2):236-244. PubMed ID: 34236581
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
